Bone marrow graft in man after conditioning by antilymphocytic serum.
Allogeneic bone marrow grafts carried out after previous administration of antilymphocytic serum alone were attempted in 16 patients. Of these, six had acute myeloblastic leukaemia, four acute lymphoblastic leukaemia, and one a blast cell crisis in polycythaemia vera. Ten of these patients were in an overt phase of the disease and resistant to chemotherapy, while nine had complete agranulocytosis. In five of these patients erythrocyte and leucocyte antigenic markers demonstrated the establishment of the graft. One patient had thalassaemia major, and four others had aplasia of the bone marrow, in one case due to chloramphenicol poisoning and in another to virus hepatitis. The grafts were successful in the last two patients and transformed their clinical condition.No signs of early acute secondary disease were noted in any of the patients, either when the donor had been given antilymphocytic serum or when he was untreated. The grafts had no adoptive immunotherapeutic effect on the acute leukaemia. These observations have clearly shown that antilymphocytic serum has an immunosuppressive effect in man when it is used alone.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002701:Chloramphenicol / Q000506:poisoning; D006506:Hepatitis A / Q000150:complications; D006648:Histocompatibility; D006801:Humans; D007945:Leukemia, Lymphoid / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008875:Middle Aged; D011087:Polycythemia Vera / Q000628:therapy; D013789:Thalassemia; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D002701:Chloramphenicol